{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:22Z","timestamp":1760147662008,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Autologous peripheral blood marrow stem cell transplantation (auto\u2010PBSCT) preceded by high\u2010dose chemotherapy is a well\u2010known method of treatment for patients with hematological cancers. Performing the procedure entails obtaining from the patient their own stem cells from peripheral blood using G\u2010CSF. Currently, various filgrastim biosimilars are widely used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim of the Study<\/jats:title><jats:p>The purpose of this study is to compare the efficacy and safety of three different biosimilars of filgrastim in PBSC mobilization in patients with hematological malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This is a retrospective analysis of 282 patients (118 women and 164 men) who underwent stem cells mobilization for auto\u2010PBSCT in the Department of Hematology in Wroclaw in 2012\u20102014. Three filgrastim biosimilars were used: Tevagrastim (95), Nivestim (92), and Zarzio (95). Ninety patients (32%) were diagnosed with multiple myeloma, 55 (19%) with Hodgkin's lymphoma, 90 (32%) with NHLs, 20 (7%) with acute myeloid leukemia, and 27 (10%) with another hematological cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean number of CD34+ cells collected during the first leukapheresis was 5.95\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg for Tevagrastim, 7.08\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg for Nivestim, and 6.8\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg for Zarzio (<jats:italic>P<\/jats:italic>\u2009&gt;\u2009.05). The necessary number of leukapheresis for patients receiving Zarzio, Nivestim, and Tevagrastim was 1.32, 1.37, and 1.66, respectively (<jats:italic>P<\/jats:italic>\u2009&gt;\u2009.05). The percentage of effective mobilizations was 88.2% for Zarzio, 86.2% for Nivestim, and 84.9% for Tevagrastim. The side effects included bone pain and headache.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jca.21750","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T09:59:18Z","timestamp":1572429558000},"page":"4-8","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The comparison of effectiveness and safety between different biosimilars of G\u2010CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto\u2010PBSCT)"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-1123","authenticated-orcid":false,"given":"Katarzyna","family":"Wicherska\u2010Paw\u0142owska","sequence":"first","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"},{"name":"Wroclaw Medical University  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Rybka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"},{"name":"Wroclaw Medical University  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Prajs","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Szmigiel","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Tyc","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Fr\u0105czak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Biedro\u0144","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Kalici\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Szymczak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Cancer and Bone Marrow Transplantation Wroclaw University Hospital  Wroclaw Lower Silesia Poland"},{"name":"Wroclaw Medical University  Wroclaw Lower Silesia Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-016-0756-x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu387"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.7.1936.bloodjournal8571936"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.12.3754.bloodjournal85123754"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.73"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1054\/blre.2000.0138"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.80"},{"key":"e_1_2_6_10_1","unstructured":"European Medicines Agency. Annex to Guideline on similar biological products containing biotechnology\u2010derived proteins as active substance: Non\u2010clinical and clinical issues guidance on similar medicinal products containing recombinant granulocyte\u2010colony stimulating factor. London: European Medicines Agency;2006.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/annex\u2010guideline\u2010similar\u2010biological\u2010medicinal\u2010products\u2010containing\u2010biotechnology\u2010derived\u2010proteins_en.pdf."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.023"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01566.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0124-7"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S123374"},{"key":"e_1_2_6_15_1","first-page":"478","article-title":"Safety and efficacy of granulocyte colony\u2010stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4\u2010year, single institute experience with different conditioning regimens","volume":"13","author":"Bassi S","year":"2015","journal-title":"Blood Transfus"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12345"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.024"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2017.12.011"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.7752"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2013.09.005"},{"key":"e_1_2_6_21_1","first-page":"203","article-title":"Biosimilar Filgrastim for progenitor\u2010cell mobilization prior to autologous transplantation : retrospective analysis of patients with multiple myeloma and lymphomas","volume":"64","author":"Fogliatto LM","year":"2018","journal-title":"Rev Bras Cancerol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14211"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.11.016"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12397"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211407367"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jca.21750","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T16:22:29Z","timestamp":1694103749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/jca.21750"],"URL":"https:\/\/doi.org\/10.1002\/jca.21750","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"type":"print","value":"0733-2459"},{"type":"electronic","value":"1098-1101"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"assertion":[{"value":"2019-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}